SCHEMBL537890

SCHEMBL537890

Nc1cc(-c2ccccc2)nn1-c1ccccc1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.83
SMN1; SMN2 Q16637 10/20 0.83
ALDH1A1 P00352 5/20 0.83
MEN1 O00255 5/20 0.83
KMT2A Q03164 5/20 0.83
TSHR P16473 2/20 0.83
GFER P55789 1/20 0.83
NPC1 O15118 9/20 0.78
MAPT P10636 7/20 0.78
KDM4E B2RXH2 4/20 0.78
STAT1 P42224 1/20 0.78
L3MBTL1 Q9Y468 3/20 0.73
NFKB1 P19838 2/20 0.73
NFKB2 Q00653 2/20 0.73
RELA Q04206 2/20 0.73
CYP1A2 P05177 2/20 0.64
CYP2C19 P33261 2/20 0.64
TP53 P04637 2/20 0.64
CYP3A4 P08684 1/20 0.64
CYP2C9 P11712 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30229798 0.96 RAB9A (0.84) RAB9ASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL14132986 0.91 RAB9A (1.00) RAB9ASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL15727491 0.90 RAB9A (0.73) RAB9ASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL17619525 0.90 RAB9A (0.69) RAB9ASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL28519664 0.88 SMN1; SMN2 (0.67) RAB9ASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL1143708 0.88 RAB9A (1.00) RAB9ASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL30230060 0.88 SMN1; SMN2 (0.73) RAB9ASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL30229682 0.88 RAB9A (0.77) RAB9ASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL28516248 0.88 RAB9A (0.77) RAB9ASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL30229823 0.88 RAB9A (0.77) RAB9ASMN1; SMN2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115537855-A Method for electrochemically synthesizing 4-iodine-5-aminopyrazole compound 阜阳师范大学 2022-12-30 CN claimed
CN-119661525-A Method for constructing pyrazolo [3,4-b ] pyridine by dehydrocyclization of 5-aminopyrazole and allyl alcohol 润华(江苏)新材料有限公司 2025-03-21 CN disclosed
US-11993729-B2 Chemical mechanical polishing composition BASF SE (DE) 2024-05-28 US disclosed
CN-118084890-A Isoxazoline-containing pyrazole amide compound as well as preparation method and application thereof 安徽农业大学 2024-05-28 CN disclosed
US-11935803-B2 Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2024-03-19 US disclosed
CN-117684188-A Electrochemical synthesis method of 5-aminopyrazole thioether compound 阜阳师范大学 2024-03-12 CN disclosed
CN-115074760-B Electrochemical synthesis method of 5-aminopyrazole-4-thiocyanate compound 阜阳师范大学 2023-11-03 CN disclosed
CN-115304607-B Pyrazolopyrimidine derivative and process for preparing same 华南农业大学 2023-06-27 CN disclosed
CN-114031556-B Synthetic method for preparing 5-amino-N-aryl-3-arylpyrazole compound by green one-pot method 温州大学 2023-03-31 CN disclosed
US-11578071-B2 Preparation of pyrazolo[3,4-B]pyridines as antimalarials UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2023-02-14 US disclosed
US-4612318-A CNS-depressant and analgesic tricyclo-[pyrazolo-[3,4-6]-pyridine] derivatives and pharmaceutical compositions thereof GRUPPO LEPETIT S.P.A. (IT) 1986-09-16 US disclosed
EP-0114273-A1 New pharmacologically active pyrazolopyridines GRUPPO LEPETIT S.p.A. (IT) 1984-08-01 EP disclosed
EP-0104522-A2 New pyrazolo(3,4-b)pyridine derivatives and process for producing them GRUPPO LEPETIT S.p.A. (IT) 1984-04-04 EP disclosed
US-4234594-A Pyrazolyl amino imidazolines as antihypertensive agents ABBOTT LABORATORIES (US) 1980-11-18 US disclosed
US-4226773-A Pyrazolyl amino imidazolines as diuretic agents ABBOTT LABORATORIES (US) 1980-10-07 US disclosed
US-4171367-A ANTIINFLAMMATORY ABBOTT LABORATORIES (US) 1979-10-16 US disclosed
US-4113718-A Basic azo dyes CIBA-GEIGY CORPORATION (US) 1978-09-12 US disclosed
US-4022799-A DYEING, PRINTING OF NATURAL AND SYNTHETIC MATERIALS BAYER AKTIENGESELLSCHAFT (DT) 1977-05-10 US disclosed
US-4001253-A NAPHTHOLACTAM DYESTUFFS BAYER AKTIENGESELLSCHAFT (DT) 1977-01-04 US disclosed
US-3950347-A NAPHTHOLACTAM DYESTUFFS BAYER AKTIENGESELLSCHAFT (DT) 1976-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578071-B2 Preparation of pyrazolo[3,4-B]pyridines as antimalarials PNPO, NOX3, G6PD RAB9A 1213/4885SMN1; SMN2 4360/4885ALDH1A1 2771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.